Layoffs are always big news in pharma, seen as an indicator of the health of the industry. Of course, the factors that eventually lead to layoffs are not simple. Often the patent cliff is to blame, but--as many of 2013's biggest cuts show--it's not always the culprit. Whatever the reason, pharma cutbacks are closely watched by investors, employees and competitors alike. Here's our report on the largest layoffs of 2013.
Chatting with the public is not in pharma's comfort zone. Drugmakers are adept at the one-way communication known as direct-to-consumer advertising, and some of them deal well with the media....
Swiss drugmaker Novartis got a mixed bag of news from European regulators Friday. It got a recommendation for its asthma drug Xolair to treat a chronic form of hives. Regulators, however, slapped down its new heart drug serelaxin, a product that Novartis is counting on bringing in more than a billion dollars a year.
European regulators handed Novartis a major setback in its quest to gain an approval for serelaxin, one of the pharma giant's top blockbuster prospects which earned "breakthrough" status at the FDA.
Novartis is in the middle of tightening its focus and cutting down on costs. But as the Swiss drugmaker goes through the evaluation process, its North American manufacturing is taking some hits. The most recent is a New York plant that employs 525, which the company now confirms it will be shutting down.
The H7N9 bird flu virus is once again spreading across China, and with evidence of human-to-human transmission also mounting, the need for effective vaccines is growing. The U.S. National Institutes of Health is trialing a Sanofi vaccine, and a number of smaller companies are also developing H7N9 vaccines.
Novartis apparently has job cuts on its January to-do list. After announcing a 500-job shuffle in Switzerland yesterday, the drugmaker now confirms that it will shutter a New York plant that employs 525 people.
Novartis launched a topical gel in India designed to treat pain associated with osteoarthritis, rheumatism and injury.
Novartis is whacking support jobs in its pharmaceutical division but said it is adding elsewhere, including in over-the-counter manufacturing and supply chain, so that the company's headcount will remain unchanged at about 15,000, Reuters reports.
To cover new drug launches, both branded and generic, Novartis is cutting 500 jobs in its pharma division in Switzerland and hiring up elsewhere. It's the latest job-trimming move at the Swiss drugmaker, which has shed thousands of jobs over the last several years.